

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. – 49. (cancelled).

50. (new) A monoclonal antibody or antigen binding fragment thereof which is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC) having an ATCC Accession Number selected from the group consisting of ATCC Accession No. PTA-2360 (MoAb 51.2), ATCC Accession No. PTA-2358 (MoAb 37.14), ATCC Accession No. PTA-2357 (MoAb 109.12), and ATCC Accession No. PTA-2359 (MoAb 26.1).

51. (new) A monoclonal antibody or antigen binding fragment thereof which binds to an antigen and competitively inhibits a second monoclonal antibody from binding to the antigen, wherein the second monoclonal antibody is a monoclonal antibody which is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC) having an ATCC Accession Number selected from the group consisting of ATCC Accession No. PTA-2360 (MoAb 51.2), ATCC Accession No. PTA-2358 (MoAb 37.14), ATCC Accession No. PTA-2357 (MoAb 109.12), and ATCC Accession No. PTA-2359 (MoAb 26.1).

52. (new) The monoclonal antibody or antigen binding fragment thereof according to claims 50 or 51, wherein the binding fragment is selected from the group consisting of Fab fragments, F(ab)₂ fragments, Fab' fragments, F(ab')₂ fragments, Fd fragments, Fd' fragments and Fv fragments.

53. (new) A pharmaceutical composition comprising the monoclonal antibody or antigen binding fragment thereof according to any one of claims 50 or 51 and a pharmaceutically acceptable carrier, excipient, or diluent.

54. (new) The monoclonal antibody or antigen binding fragment thereof according to any one of claims 50 or 51, further comprising a detectable moiety.

55. (new) The monoclonal antibody or antigen binding fragment thereof according to claim 54, wherein the detectable moiety is selected from the group consisting of a fluorophore, a chromophore, a radionuclide, a chemiluminescent agent, a bioluminescent agent and an enzyme.

56. (new) A hybridoma cell line which is deposited at the American Type Culture Collection (ATCC) and having ATCC Accession Number selected from the group consisting of ATCC Accession No. PTA-2360 (MoAb 51.2), ATCC Accession No. PTA-2357 (MoAb 109.12), ATCC Accession No. PTA-2358 (MoAb 37.14), and ATCC Accession No. PTA-2359 (MoAb 26.1).

57. (new) A hybridoma cell line which produces a monoclonal antibody which binds to an antigen and competitively inhibits a second monoclonal antibody from binding to the antigen, wherein the second monoclonal antibody is a monoclonal antibody which is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC) having an ATCC Accession Number selected from the group consisting of ATCC Accession No. PTA-2360 (MoAb 51.2), ATCC Accession No. PTA-2358 (MoAb 37.14), ATCC Accession No. PTA-2357 (MoAb 109.12), and ATCC Accession No. PTA-2359 (MoAb 26.1).